In 2008, the Food and Drug Administration (FDA) approved the use of the first-in-class CXCR4-inhibitor, plerixafor (AMD3100; Mozobil®), in association with granulocyte colony-stimulating factor (G-CSF) for the mobilization and the collection of PBSC in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) [38,39,40]#. This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.